Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Israeli-Originated High-Techs Highlighted at Israel Life Science Forum 2013
March 25, 2013
- Merck Serono to Develop Anticancer Drugs for Asian Patients at R&D Hub in Tokyo
March 22, 2013
- New Product Launches “On Track,” Sales Brisk: Otsuka Holdings Pres. Higuchi
March 22, 2013
- SSRI Predicts SGLT-2 Inhibitor Market to Grow to around 60 Billion Yen in 5th Year after Launch
March 22, 2013
- Japan Pharmas Accelerating Drives to Set Up Medical Affairs Units
March 21, 2013
- MHLW Lifts All-Case Surveillance for Treakisym: SymBio, Eisai
March 19, 2013
- Alcon Japan, Kyowa Kirin Adjust Shipments of Anti-Allergy Drugs
March 19, 2013
- Daiichi Sankyo to File Prasugrel for Cardiovascular Disease in PCI Patients in Japan
March 19, 2013
- Pfizer Japan Launches OAB Treatment Toviaz
March 19, 2013
- Generic Companies Increasing Focus on Fast-growing Oncology Market; Shift to Overseas Production Will Spur Cost Competition
March 18, 2013
- Eisai Appoints Its First Female Executive
March 18, 2013
- MHLW Lifts All-Case Surveillance for Novartis' Lucentis
March 18, 2013
- Nihon Pharmaceutical Industry Voluntarily Recalls Revinbace Tablets 10 mg, Temporarily Suspends Sales
March 18, 2013
- Eisai Eyes Sales of 50 Billion Yen in Asian Generic Biz within 5 Years
March 15, 2013
- Shionogi, Kyoto University to Collaborate on Research for AD Treatment
March 15, 2013
- Eli Lilly Japan Files Tadalafil for BPH, 3rd NDA for Same API
March 15, 2013
- Astellas Files NDA in Japan for SGLT-2 Inhibitor Ipragliflozin
March 15, 2013
- API Corporation to Establish Production Base for Drug Substances, Intermediates in India
March 15, 2013
- Astellas Grants US Firm Global Rights to Ceftolozane
March 14, 2013
- Eli Lilly Japan’s 2012 Sales Surge 10% on Brisk Zyprexa; NHI Price Cut Countered
March 14, 2013
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…